The award, which is sponsored by Zoetis, was given online this year at an event hosted by sports television presenter Mark Durden-Smith and Chloe Ryan, the editor of Poultry Business.
William was brought up on a sheep farm in Nottinghamshire and as a youngster bred rare breed poultry, selling eggs to local people in the village. He graduated at Nottingham University, did a poultry internship with a practice in the North West and worked there initially. Four years ago, he set up his own practice Avivets, at High Legh in Cheshire, dedicated to the poultry and game bird sector. He guest lectures at the Universities of Nottingham and Surrey and is an official veterinarian for avian exports. He sits on the RSPCA’s technical standards advisory board and was recently appointed veterinary advisor for the NFU poultry board.
Chloe Ryan said he had impressed the judges ‘with his enthusiasm for poultry veterinary knowledge and entrepreneurship. He has shown an excellent level of dedication, enriching his experience and qualifications through continuous professional development to farms and flocks as evidenced by glowing praise from a long list of clients.’
Lucy Berriman, Zoetis UK poultry national account manager, said: “Zoetis is proud to be sponsors of this new award for the industry’s poultry vets.
"It gives hardworking individuals the chance to shine and illustrate their commitment to the poultry industry. Congratulations to Will for this fabulous achievement, and well done to the other two finalists."
The other finalists were Helena Brewer, who joined the Poultry Health Services team at Sheriff Hutton, near York, after studying at the Royal (Dick) School at Edinburgh and the Royal Veterinary College, and Henry Lamb, who has worked at Crowshall Veterinary Services in Norfolk since graduating at the Royal Veterinary College.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
Boehringer Ingelheim Vetmedica Ltd has announced that Metacam is now available for use in pigs as an oral suspension.
Metacam, which contains the non-steroidal anti-inflammatory drug (NSAID) meloxicam, is indicated for the treatment of non-infectious locomotor disorders to reduce inflammation and signs of lameness. It is also licensed for the treatment of mastitis-metritis-agalactia (MMA) syndrome in sows, when used alongside appropriate antibiotic therapy. MMA is a multifactorial condition that can threaten the health of the sow and the lives of her piglets due to a marked decrease or complete cessation in milk production.
Boehringer says treatment with Metacam15 mg/ml oral suspension helps control inflammation and pain associated with the condition, thereby helping to restore productivity and wellbeing in the sow and her offspring.
Metacam 15mg/ml oral suspension for pigs supplements the existing injectable formulation and has been introduced to its increase flexibility and ease of use, and to reduce the potential stress than can be caused when injecting newly-farrowed sows. The palatable suspension can be given mixed with a small quantity of feed or can be administered directly into the mouth.
Hysolv says the vaccine, which was developed by IDT Biologika, has been used successfully in Germany, where 1.7 million doses have been prescribed. The company says field trials have shown that vaccination not only protected against clinical signs of influenza but also resulted in improvements in reproduction and piglet performance.
Two 1 ml doses of the inactivated vaccine can be injected intramuscularly three weeks apart to pigs from 56 days old, providing immunisation to the majority of animals within seven days.
Hysolv director, Geoff Hooper said: "Swine flu can be devastating to a herd and this vaccine will broaden protection, particularly when used with our existing vaccine Respiporc FLU3, which we are strongly advising."
Respiporc FLU3 protects against three other strains of swine flu (H1N1, H1N2 and H3N2). Hysolv says that when used together, the two vaccines protect pigs against the most relevant strains in the British Isles.
Geoff added: "There have been several flu pandemics throughout the years – the latest in 2009. It is not possible to predict the emergence of a pandemic strain accurately but this vaccine combined with Respiporc FLU3 will greatly decrease the chance of pigs becoming infected."
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
MSD Animal Health has announced a new claim for Bovilis BVD and Bovilis IBR Marker Live vaccines which means they can be mixed and administered in a single syringe.
MSD says the new mixing claim will offer significant advantages in herd health planning when controlling two of the more important infectious diseases in cattle.
Bovine Viral Diarrhoea (BVD) and Infectious Bovine Rhinotracheitis (IBR) remain major threats to cattle health and productivity. Vaccinations are commonly given at housing and/or turnout, which are both busy times for veterinary surgeons and on the farm in the herd health planning calendar.
The mixed vaccines are suitable only for booster vaccinations of animals from 15 months of age previously vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD. The mixed vaccine needs to be used within three hours.
MSD says the mixing procedure is clear and easy, but there is an instructional video here: http://www.msd-animal-health.co.uk/Mixing_bovilis_BVD_Bovilis_IBR-Marker_Live.aspx
First you need to complete your VetSurgeon Profile, in particular the last four sections: "Qualified at", "Interests", "Interested in collaborating on" (aka goals) and "Memberships".
Then visit VetSurgeon Connect and click the button marked "Share My Location". This will activate the map beneath, allowing you to see local colleagues with common interests. It will also pin you on the map, but only in front of logged in members of the site with whom you have a common interest.
One area of common interest is the connection between general practitioners and referral practitioners. Referral practitioners who have shared their location are pinned on the map and can be seen by general practitioners (who can also filter them by discipline).
It is hoped that this will help create a more vibrant referral marketplace, as it offers referral practitioners who do not have big marketing budgets a way to connect with local general practitioners.
The system also matches VetSurgeon members by a number of other criteria. So for example, if you specify 'Qualified at' in your profile, it will display anyone else who went to the same vet school. If you display a leisure interest like cycling in your profile, it'll display other vets in your area who also like cycling.
If you display a clinical interest, such as oncology, it'll show you others in the area with the same interest.
The same thing happens with 'Interested in collaborating on', which connects you with others working towards the same goals, which can be business goals like practice ownership or a learning goals, such as CPD or being a mentor/mentee.
Lastly, if you specify your membership of a special interest veterinary association, the system will show you other members who are in your area.
VetSurgeon Editor Arlo Guthrie said: "It’s kind of a professional matchmaking service designed to make it easier than ever before for veterinary surgeons and others to hook up and collaborate on all sorts of different things.
"It may be you think you know everyone you need to know in your area already. But so often we think we know people, then find out we didn’t know about a shared passion for something, whether it be a professional or a leisure interest. Indeed, I think the system could be just as useful in connecting members to go on a bike ride together as it is to help them collaborate on CPD or on achieving additional qualifications."
Chris Taylor from Swann-Morton said: "We are really pleased to be part of this initiative which should help to bring the veterinary community closer together through shared experiences and knowledge."
Arlo added: "I’m very grateful for Swann Morton’s support. If you are too, you can show it by visiting the company's website and having a quick browse of the latest products in its veterinary range at www.swann-morton.com."
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Reference
The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.
To win, OVs are asked to submit a question to a speaker of their choice by Monday 12 August.
The question judged the most interesting will win the free ticket and five runners up will each receive a 50% discounted ticket. In each case, the OV can choose their preferred day to attend.
The full programme can be found at: https://officialvet.com/programme/ and questions can be submitted to enquiries@improve-ov.com or by private message through Facebook at https://www.facebook.com/officialvet/
Improve says this year's speakers will address an increasing threat from notifiable diseases in the UK, with evidence of M. bovis infection linked to a raw pet food diet identified in cats, an outbreak of equine viral arteritis in Dorset and cases of African swine fever recently reported in western Europe. The programme includes small animal and farm animal focused lecture streams on both days, an equine stream on the first day and a series of specialist workshops on the second.
Dr Andrew Soldan (pictured right), Veterinary Director at APHA, said: "Notifiable diseases are an ongoing threat to the health and welfare of animals and our farming industries in the UK. Animal keepers and vets play a vital role in their early detection. We’re particularly concerned by the risk of African swine fever following the disease being found in wild boar in Belgium last year.
"Small animal and mixed practice OVs can help us reduce the risk of ASF infecting UK pigs by informing pig keepers of the risk and advising them of the importance of not feeding kitchen scraps and catering waste to pigs.
"We’re currently in the vector season so bluetongue is another disease to look out for in cattle and sheep. Providing advice to livestock farmers on how they can minimise the risk of its introduction through vaccination and checking the source of imported animals is another important role for OVs."
David Babington MRCVS, Business Development Director at Improve International, said: "OVs play a crucial role in monitoring our exposure to notifiable diseases and in alerting us to possible outbreaks. For this reason, providing a full update on the current disease status is an important element of this year’s programme, though we will also cover other important topics, including illegal puppy imports, pet travel and, inevitably I’m afraid, Brexit."
For more information on the Official Veterinarian Conference and exhibition or to register visit: www.officialvet.com.
Vetoquinol UK Limited has launched Ceftiocyl: a ready-to-use formulation containing 50mg/ml ceftiofur for use in cattle and pigs.
In cattle, Ceftiocyl can be used for the treatment of respiratory disease, acute interdigital necrobacillosis and acute post-partum metritis. In pigs, Ceftiocyl is licensed for the treatment of respiratory disease. Ceftiocyl has the added benefit of traceability stickers which are attached to each vial making it easier and quicker to record and monitor on-farm usage.
Susan Mitchell, Large Animal Product Manager at Vetoquinol UK Ltd said, 'We are delighted to be expanding our large animal anti infective range offering. Marbocyl 10% has been used for acute mastitis in the dairy sector for many years, the addition of Ceftiocyl to our portfolio enables us to provide a cost-effective treatment for both metritis and lameness.'
1. Willshire, J.A. & Bell, N, J. (2009) An economic review of cattle lameness. Cattle Practice 17, 136-141.
Virbac has been granted a Limited Marketing Authorisation in the UK for its Gudair vaccine, indicated for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (MAP).
MAP is the causal organism for Johne's Disease, a chronic infection of the intestinal system for which there is no cure.
According to Virbac, Johne's Disease enters most flocks following the introduction of infected stock, often breeding rams, bought at markets without checks on disease provenance. It is then spread by the faeces of often apparently healthy animals but which can contain huge numbers of MAP. The main clinical sign is a thin ewe resulting in poor productivity followed by inevitable death. It can be passed between sheep and cattle.
Ovine Johne's Disease (OJD) in sheep is widespread in Australia where annual death rates of up to 17% have been seen in infected flocks. Virbac says that trials conducted there have demonstrated that vaccination with Gudair can reduce the number of deaths due to OJD by 90% and reduce the numbers of OJD-causing organisms excreted in sheep faeces by 90%.
Ken Sibley MRCVS, Technical Advisor at Virbac says that the number of infected flocks in the UK is unknown and the disease often remains undiagnosed: "Johne's Disease can be a significant cause of loss in infected sheep flocks because of reduced productivity and high culling rates. Vaccination provides the only possible assurance when sourcing sheep from potentially infected flocks and will help to reduce losses from the disease should a farmer inadvertently introduce sheep into an infected flock.
"Lambs identified as replacements should generally be vaccinated between 4 and 16 weeks of age, subcutaneously behind the ear. Sheep over 16 weeks of age can also be vaccinated as this will reduce shedding of organisms in infected animals while bought-in replacements can be vaccinated on arrival at the farm. Sheep require only one vaccination for their lifetime.
"Following its success in Australia, we are delighted to be able to offer Gudair to veterinary surgeons in the UK."
For further information, contact your Virbac territory manager or call: 01359 243243
In the Somerset cull area, TB incidence has fallen from 24% before culling started to 12% in year four of the cull, while in Gloucestershire it has fallen from 10.4% to 5.6%.
The Government says the findings are in line with expectation based on the scientific evidence from the Randomised Badger Culling Trial which underpins the approach to tackling bovine TB – and demonstrate progress is being made in delivering the 25-year TB eradication strategy in England to rid our farmers of the impacts of this terrible disease.
Defra has also announced additional measures being taken to help control the disease, including licences for badger control in 11 new areas and the opening of a new round of applications for the Badger Edge Vaccination Scheme grants.
Farming Minister George Eustace said: "Bovine TB remains one of the greatest animal health threats to the UK. There is no single measure that will provide an easy answer which is why we are committed to pursuing a wide range of interventions to protect the future of our dairy and beef industries and eradicate the disease within 20 years.
"No one wants to be culling badgers forever so the progress reported today is encouraging."
BVA President John Fishwick said: "We continue to support a comprehensive and evidence-based approach to tackling bovine TB, including the use of badger culling in a targeted, effective and humane manner. TB is a devastating disease and we welcome the positive results emerging in Somerset and Gloucestershire, where licensed culling has now been in place for four years. The recent results in Dorset, indicating a slight upward trend in the incidence of bovine TB, present some cause for concern and we would like to see further investigation of the cattle and wildlife situation in that area.
"BVA supports the principle of badger controls within the Low Risk Areas (LRAs) of England where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy. We are largely reassured by the greater clarity provided on the decision-making process on how and where badger controls will be introduced in the LRAs. We recognise the expertise and professional judgement of veterinary and scientific colleagues in government who have made the decision to extend the cull in this area, but we would welcome further evidence regarding the level of TB infection in the wildlife reserve in Cumbria as this becomes available.
"Halting the spread of bovine TB is essential and it is vital that we use every available tool in the toolbox to support the Government’s aim to make England TB free. We therefore welcome both the introduction of tighter cattle controls where needed and the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. We would also like to see a commitment to funding of further research in this area."
Photo: Coatesy/Shutterstock
Novartis Animal Health UK Ltd has announced the launch of CLiKZiN Pour On for sheep, a short meat withhold period (MWP) product that can be used throughout Spring and Summer for the prevention of blowfly strike in sheep and lambs.
CLiKZiN is a ready-to-use water-based product that protects sheep for eight weeks, and has a meat withhold period of seven days. The product is a line extension of CLiK which offers a longer period of protection at 16 weeks and has a longer withhold period of 40 days. Novartis says that used in conjunction with CLiK, CLiKZiN offers versatile protection throughout the year.
The launch of CLiKZiN comes at the same time that Vetrazin has been reformulated, resulting in a longer meat withhold period for sheep treated with the product.
Thomas Tiley MRCVS from Novartis Animal Health said: "Farmers need reliable protection from the repugnant threat of blowfly strike. CLiKZiN provides eight weeks blowfly prevention together with the trusted performance and safety record associated with CLiK. It also offers the greater flexibility of a seven day meat withhold.
"This makes CLiKZiN ideally suited for a variety of production schedules and stock including lambs for slaughter and pre-shearing ewes."
Blowfly strike can be devastating to sheep, causing severe impact on the welfare of the animal. Within days of a blowfly laying its eggs, clinically normal sheep can be afflicted with flesh eating maggots. This makes prompt and effective treatment critical.
National Sheep Association Chief Executive Peter Morris said: "Fly strike is a terrible burden to the sheep industry both in terms of the welfare of the sheep and economically.
"Having a product available that gives effective prevention against fly strike whilst at the same time having a withdrawal period which does not impinge on the ability of the sheep farmer to market lambs is very welcome. The sheep farmers' armoury against the every day afflictions which affect sheep has been significantly enhanced."
The company says Taurador Pour-on provides a stress-free, easy to use treatment, with persistent activity against a large number of cattle parasites, therefore ensuring effective coverage over long periods of the grazing season.
Matthew Swanborough BVSc MRCVS, Veterinary Advisor for Norbrook, said: "The farming industry will be aware that heavy worm burdens can significantly affect the health and productivity of cattle, potentially as much as £100 per head of cattle. We cannot simply ignore these parasites but we must tackle them responsibly. A comprehensive worming strategy is a vital component of any animal health plan, which should be composed of management strategies and any necessary anthelmintic treatments."
Norbrook highlights the product's efficacy against the gutworms Osterstagia osterstagi, Cooperia oncophora and lungworm, Dictyocaulus viviparous, with persistent action against these parasites for 35 days, 28 days and 42 days respectively.
Doramectin, the active ingredient in Taurador, is an anthelmintic belonging to the macrocyclic lactones (3-ML) group, along with ivermectins. Norbrook says both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods.
Dr Leigh Sullivan, Norbrook Large Animal Product Manager, said: "Taurador is the company’s thirteenth new product introduction in the last four years and it is a significant addition to our portfolio. Internal parasites such as gutworms and lungworm can have a serious impact on animal health and welfare, as well as financial implications for farmers, so it is great to be able to provide another product to help reduce the economic impact of these parasites."
Taurador is available in three different pack sizes (1L; 2.5L and 5L) and an appropriate dosing applicator is also available.
The company says industry estimates are that 12 million accessible breeding ewes (91%) are not vaccinated against enzootic abortion in the UK, and that this should concern all practitioners with sheep clients.
Any flock with an abortion rate of over 2% could, it says, be suffering from the disease, and at a cost of £85 per aborted ewe, those are losses producers can ill-afford to ignore.
Stephenie Clarke from Ceva said: "Abortion remains one of the most significant reasons for loss in sheep flocks and an abortion storm can lead to crippling results on farm.
"Enzootic abortion caused by C. abortus remains the main cause of ovine abortion in the UK1 and once in a flock, takes time to control as exposed ewes can become latently infected."
Assure Ewe is a subsidised blood testing scheme open to all flocks with 50 or more breeding ewes. In contrast to other schemes, evidence of an abortion does not need to have taken place.
Blood samples should be collected from six ewes, with full farm and vet details also supplied. Upon results, Ceva says it will share information with the participating veterinary surgeon to discuss with the farmer.
Stephenie added: "Assure Ewe is a very user-friendly, simple scheme that will help facilitate conversations between vets and farmers while, at the same time, providing useful testing information to vets. Ceva encourages evidence based veterinary decisions, and this is just one example of such an initiative."
If C. abortus is identified in a flock, a veterinary-devised plan combining vaccination with Cevac Chlamydia, biosecurity and only purchasing stock from accredited flocks will assist disease control and eventual eradication.
For further information about the scheme, contact your Ceva territory manager.
Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
Tulaven is licensed for the treatment and metaphylaxis of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis.
Tulaven can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
Tulaven is also is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.
Ceva highlights that Tulaven is the only tulathromycin available in CLAS (Ceva Layered Anti Shatter) vials1, which have less impact on the environment2, are easier to handle3 and transport4, and are preferred by farmers5.
Cuneyt Seckin, Managing Director of Ceva Animal Health, said: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of Tulaven is the next addition to this range, enabling us to offer even more support to vets and farmers.”
For further information, contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
References
This only affects batch number C967336A, expires before 07/2020. Any other batches of Tylan 200 Injection are not affected and may continue to be distributed.
Elanco is contacting wholesale dealers and veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information regarding the recall, please contact Ms Victoria Haslingden 01256 779519 or email elanco_orders@lilly.com
Richard was nominated for his dedication to improving rabbit welfare, in particular for his work in getting a new vaccine in to the UK to protect all pet rabbits against an emerging deadly disease (RVHD2).
Richard qualified from Liverpool University in 1994, obtained his Certificate in Zoological Medicine in 2001 and his Diploma in Zoological Medicine in 2010, while he was an RWAF resident. Richard is also registered as a recognised RCVS Specialist in Zoo and Wildlife Medicine (one of only 30 in the world).
Rae Todd, CEO of the Rabbit Welfare Association & Fund said: "We're incredibly proud of Richard for all of his hard work and delighted that he's received recognition for his work. We all owe Richard a huge debt of gratitude for his commitment to the industry and for protecting all pet rabbits. So far, we estimate in the region of 70,000 rabbits have been vaccinated thanks to Richard."
Co-host of the awards, Matt Baker said: "I am truly humbled by the hard work and dedication of individuals and organisations who are passionate about improving animal welfare and would like to congratulate both the finalists and the award winners who are making a real difference to the lives of animals both in the UK and abroad."
Cuneyt Seckin, managing director of Ceva Animal Health, added: "The Ceva Animal Welfare Awards go from strength to strength, both in terms of the number and quality of entries that we receive during the nomination process and the dedication, commitment and enthusiasm of the finalists and winners who often go above and beyond the call of duty in the name of animal welfare."
Other winners this year included:
Welfare Nurse of the Year Award in association with Agria Pet InsuranceAdina Valentine, Blue Cross Animal Hospital in Grimsby
Charity Team of the Year supported by PDSAThe Dog Breeding Reform Group
Charitable Contribution of the Year supported by Blue Cross Helen Whiteside, Canine Research Associate at Guide Dogs
Farm Animal Welfare Award supported by R.A.B.I. and NADISThe University of Nottingham Dairy Herd Health Group
International Cat Care Welfare of the Year AwardMaria Pinto Teixeira from Animals de Rua (AdR) in Portugal
The award recognises an exceptional farm vet who has been working in the dairy industry for three to five years and contributed significantly to the health and wellbeing of the herds under their care.
Rob joined LLM Vets after graduating from Cambridge University Vet School in 2017. He has particular interests in lameness, calf rearing and housing design. He said: “Since joining LLM, I have thrown myself into all aspects of the practice – from the Agricultural Show season to driving LLM’s BVD eradication efforts and revamping our herd health planning scheme. My role in practice management is also growing. I currently oversee work for the Johnes CHeCS programme and help to guide our industry-leading team of VetTechs."
He added: “I find the interaction between dairy cattle and their environment fascinating and, following some specialist training I undertook with the Dairyland Initiative in Wisconsin, I’ve been helping our farmers to make major changes to their cow and calf housing, particularly by improving ventilation.”
CREAM judge Rob Drysdale said: “Rob Hall really stood out because of the additional services he’s trying to offer, for instance, getting involved in the Stamping Out BVD campaign and utilising his specialist skills in calf housing ventilation to increase welfare standards. Rob would be a real asset to any farm or vet business.”
Charlotte Read, Key Account Manager – Farm, at Krka, added: “Newly qualified vets represent the future of this exciting and rapidly-evolving profession so we are particularly delighted to have the opportunity to highlight their achievements. Krka is proud to support the UK’s dairy sector and we congratulate both Rob and Rupert on the huge contribution they are making to their clients and their practices.”
The new vaccine offers up to 12 months' immunity against three of the biggest diseases that cause reproductive failures in pigs.
Alexandre Carvalho, business unit manager for pigs at MSD Animal Health, says the vaccine has the broadest protection against Leptospira on the market, offering protection against nine different serogroups including, Australis and Pomona.
He added: "This vaccine also includes protection against the Tarassov serogroup, which is unique to the product.
"It’s important to note that PORCILIS Ery+Parvo+Lepto can be used for mass vaccination and during pregnancy, which hasn’t been possible with previous products."
Bovilis Nasalgen-C can be used for the active immunisation of calves from the day of birth onwards to reduce clinical signs of upper respiratory tract disease and nasal viral shedding from infection with BCoV.
MSD says respiratory disease in UK calves is widespread and comes at a high cost from an emotional and business productivity perspective.
It is also continually highlighted as a critical area for overuse of antibiotics.
Despite all this, there is an under use of vaccination in the UK cattle sector1.
Speaking at BCVA last week, Paul Burr MRCVS, director of Biobest Laboratories said: “Recent UK studies show bovine coronavirus being the most prevalent virus found in routine disease screening and nasal swab samples taken during a bovine respiratory disease outbreak.
"BCoV was found in 39% of over 400 nasal swab samples taken between 2020 and 2022 from BRD affected cattle on UK farms2.”
Kat Baxter-Smith, veterinary adviser with MSD Animal Health, said: “Whilst the pathogenicity of BCoV within the BRD complex remains an unknown quantity, its ubiquitous presence in the UK cattle population – and the recent human experience of coronavirus as a significant respiratory pathogen – suggests a need for a re-evaluation of BRD control by vets and farmers.
“Just as coronavirus is a pathogen associated with the common cold and Covid-19, BCoV is a proven pathogen that directly impacts the calf respiratory tract.
"Consequently, the availability of this new BRD vaccine presents veterinary professionals with another tool in their armoury to improve control of this costly disease.
“If diagnostics suggest BCoV is implicated in any BRD problem, the availability of Bovilis Nasalgen-C allows UK cattle farmers to effectively administer protection for young calves via a single 2ml intranasal dose that can quickly reach the site of action.
"This will support the development of immunity against BCoV early in life, the onset of which starts five days after administration and has a 12-week duration.”
Bovilis Nasalgen-C comes can be used on the same day with Bovilis INtranasal RSPÔ Live, which offers protection against both Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3).
Bovilis Nasalgen-C can be stored for up to 24 hours at room temperature after reconstitution, can be given to cattle using a syringe or applicator device and is available in one, five and 20 dose packs, suitable for both small and large herds.
Being an intranasal vaccine, Bovalto Respi IN triggers mucosal immunity in the nasal passages and throat area. It can be delivered from 10 days of age without the need for a booster and provides immunity for 12 weeks, from 10 days after vaccination.
Boehringer says it has also been shown to be effective in the face of MDA (maternally derived antibodies).
The new bottle now has a wider neck, which apparently makes for a better fit with the accompanying Respisafe applicator and nozzle.
Brand manager Matt Yarnall said: "The Respisafe applicator ensures that vaccination is a comfortable process for both farmer and calf and the improved fit will make the job even easier.
"With an intranasal vaccine, it is important that the vaccine droplets coat the mucosa of the nasal passages, where they can begin to work. If they are too big, then the vaccine can run out of the nose, and if too small then the droplets are carried into the lungs and are wasted. The Respisafe system ensures that the optimum size of droplet is administered to the right place in an efficient and easy way.”
Bovalto Respi Intranasal protects against the two main respiratory viruses – RSV and PI3, and during its development it was tested against current strains, that are associated with causing disease in cattle1.
Stock of the new bottles will start to enter circulation with vets from mid-July, with an expectation that the existing version will still be in circulation until early in the new year.